Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

Multimodal treatment including radical prostatectomy might lead to improved survival in patients with oligometastatic prostate cancer treated with ADT. Men with oligometastatic prostate cancer (OmPCa) ...

PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.

Prostate cancer is highly treatable when detected early, as it carries a favourable prognosis. Therefore, awareness among ...

DelveInsight's Castration-sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, CSPC emerging drugs, market share of individual ...

Late-onset depression is increasingly recognized as a major challenge in older cancer survivors, who show a higher prevalence ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Policy, precision medicine, and new ways of delivering therapeutics were popular topics in 2025 among readers of Evidence-Based Oncology ™ (EBO), the multistakeholder cancer care publication of The ...